论文部分内容阅读
目的探讨pSilencer2.0-c-Met-siRNA重组质粒对人喉癌Hep-2细胞裸鼠移植瘤生长的影响。方法采用裸鼠喉癌皮下荷瘤模型模拟c-Met-siRNA基因治疗实验,观察c-Met-siRNA重组质粒的抗瘤疗效,Western-blot法检测重组质粒对c-Met基因及MMP-2、MMP-9、VEGF基因表达的影响。结果肿瘤接种后第35 d,重组质粒组肿瘤体积为13 827 mm3,与对照组相比差异有统计学意义(P<0.01);重组质粒组瘤体内c-Met、MMP-2、MMP-9、VEGF基因表达率比对照组明显降低(P<0.05)。结论pSilencer2.0-c-Met-siRNA重组质粒能明显抑制人喉癌Hep-2细胞移植裸鼠成瘤后的生长,siRNA表达质粒介导的基因治疗有希望成为喉癌靶向性c-Met治疗的新策略。
Objective To investigate the effect of pSilencer2.0-c-Met-siRNA recombinant plasmid on the growth of transplanted human laryngeal carcinoma Hep-2 cells in nude mice. Methods The nude mice model of subcutaneous tumor of laryngeal carcinoma was used to simulate the gene therapy of c-Met-siRNA. The anti-tumor effect of c-Met-siRNA recombinant plasmid was observed. The effect of recombinant plasmid on c-Met gene and MMP- MMP-9, VEGF gene expression. Results The tumor size of the recombinant plasmids was 13 827 mm3 on the 35th day after tumor inoculation, which was significantly different from the control group (P <0.01). The expression of c-Met, MMP-2 and MMP-9 , VEGF gene expression rate was significantly lower than the control group (P <0.05). Conclusion The recombinant plasmid pSilencer2.0-c-Met-siRNA can significantly inhibit the growth of human laryngeal carcinoma Hep-2 cells transplanted into the nude mice after the tumorigenesis. SiRNA plasmid-mediated gene therapy is promising as a target of laryngeal carcinoma targeting c-Met New strategy for treatment.